Measurements of adiposity as prognostic biomarkers for survival with anti-angiogenic treatment in epithelial ovarian cancer: An NRG Oncology/Gynecologic Oncology Group ancillary data analysis of GOG 218

K. N.Slaughter Wade, M. F. Brady, T. Thai, Y. Wang, B. Zheng, R. Salani, K. S. Tewari, H. J. Gray, Jamie N Bakkum-Gamez, R. A. Burger, K. N. Moore, M. A. Bookman

Research output: Contribution to journalArticle

Abstract

Objective: Adiposity has been hypothesized to interfere with the activity of bevacizumab (BEV), an anti-angiogenic agent. Measurements of adiposity, BMI, surface fat area (SFA), and visceral fat area (VFA) were investigated as prognostic of oncologic outcomes among patients treated with chemotherapy, with or without BEV, on GOG 218, a prospective phase III trial. Method: Pretreatment computed tomography (CT) for 1538 GOG 218 participants were analyzed. Proportional hazards models assessed association between adiposity and overall survival (OS) adjusted for other prognostic factors. The predictive value of adiposity as a function of BEV treatment was assessed in 1019 patients randomized to either chemotherapy (CT) + placebo (P) → P or CT + BEV → BEV. Results: After adjusting for prognostic factors, SFA was not associated with the overall hazard of death (p = 0.981). There was a non-significant 0.1% (p = 0.062) increase in hazard of death associated with a unit increase in VFA. When comparing the treatment HRs for patients who did and did not receive BEV, there was no association with SFA (p = 0.890) or VFA (p = 0.106). A non-significant 0.8% increase in the hazard of death with unit increase in BMI (p = 0.086) was observed. BMI values were not predictive of a longer survival for patients with BEV vs placebo (p = 0.606). Conclusion: Measures of adiposity strongly correlated to one another but were not predictive of efficacy for BEV. VFA is a weak prognostic factor.

Original languageEnglish (US)
JournalGynecologic oncology
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Adiposity
Biomarkers
Survival
Intra-Abdominal Fat
Fats
Therapeutics
Tomography
Placebos
Drug Therapy
Bevacizumab
Ovarian epithelial cancer
Proportional Hazards Models

Keywords

  • Adiposity
  • Epithelial ovarian cancer
  • NRG
  • Prognostic biomarkers

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynecology

Cite this

Measurements of adiposity as prognostic biomarkers for survival with anti-angiogenic treatment in epithelial ovarian cancer : An NRG Oncology/Gynecologic Oncology Group ancillary data analysis of GOG 218. / Wade, K. N.Slaughter; Brady, M. F.; Thai, T.; Wang, Y.; Zheng, B.; Salani, R.; Tewari, K. S.; Gray, H. J.; Bakkum-Gamez, Jamie N; Burger, R. A.; Moore, K. N.; Bookman, M. A.

In: Gynecologic oncology, 01.01.2019.

Research output: Contribution to journalArticle

Wade, K. N.Slaughter ; Brady, M. F. ; Thai, T. ; Wang, Y. ; Zheng, B. ; Salani, R. ; Tewari, K. S. ; Gray, H. J. ; Bakkum-Gamez, Jamie N ; Burger, R. A. ; Moore, K. N. ; Bookman, M. A. / Measurements of adiposity as prognostic biomarkers for survival with anti-angiogenic treatment in epithelial ovarian cancer : An NRG Oncology/Gynecologic Oncology Group ancillary data analysis of GOG 218. In: Gynecologic oncology. 2019.
@article{21b25cdbdedc4eff9251e27befc06e95,
title = "Measurements of adiposity as prognostic biomarkers for survival with anti-angiogenic treatment in epithelial ovarian cancer: An NRG Oncology/Gynecologic Oncology Group ancillary data analysis of GOG 218",
abstract = "Objective: Adiposity has been hypothesized to interfere with the activity of bevacizumab (BEV), an anti-angiogenic agent. Measurements of adiposity, BMI, surface fat area (SFA), and visceral fat area (VFA) were investigated as prognostic of oncologic outcomes among patients treated with chemotherapy, with or without BEV, on GOG 218, a prospective phase III trial. Method: Pretreatment computed tomography (CT) for 1538 GOG 218 participants were analyzed. Proportional hazards models assessed association between adiposity and overall survival (OS) adjusted for other prognostic factors. The predictive value of adiposity as a function of BEV treatment was assessed in 1019 patients randomized to either chemotherapy (CT) + placebo (P) → P or CT + BEV → BEV. Results: After adjusting for prognostic factors, SFA was not associated with the overall hazard of death (p = 0.981). There was a non-significant 0.1{\%} (p = 0.062) increase in hazard of death associated with a unit increase in VFA. When comparing the treatment HRs for patients who did and did not receive BEV, there was no association with SFA (p = 0.890) or VFA (p = 0.106). A non-significant 0.8{\%} increase in the hazard of death with unit increase in BMI (p = 0.086) was observed. BMI values were not predictive of a longer survival for patients with BEV vs placebo (p = 0.606). Conclusion: Measures of adiposity strongly correlated to one another but were not predictive of efficacy for BEV. VFA is a weak prognostic factor.",
keywords = "Adiposity, Epithelial ovarian cancer, NRG, Prognostic biomarkers",
author = "Wade, {K. N.Slaughter} and Brady, {M. F.} and T. Thai and Y. Wang and B. Zheng and R. Salani and Tewari, {K. S.} and Gray, {H. J.} and Bakkum-Gamez, {Jamie N} and Burger, {R. A.} and Moore, {K. N.} and Bookman, {M. A.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.ygyno.2019.07.020",
language = "English (US)",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Measurements of adiposity as prognostic biomarkers for survival with anti-angiogenic treatment in epithelial ovarian cancer

T2 - An NRG Oncology/Gynecologic Oncology Group ancillary data analysis of GOG 218

AU - Wade, K. N.Slaughter

AU - Brady, M. F.

AU - Thai, T.

AU - Wang, Y.

AU - Zheng, B.

AU - Salani, R.

AU - Tewari, K. S.

AU - Gray, H. J.

AU - Bakkum-Gamez, Jamie N

AU - Burger, R. A.

AU - Moore, K. N.

AU - Bookman, M. A.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Objective: Adiposity has been hypothesized to interfere with the activity of bevacizumab (BEV), an anti-angiogenic agent. Measurements of adiposity, BMI, surface fat area (SFA), and visceral fat area (VFA) were investigated as prognostic of oncologic outcomes among patients treated with chemotherapy, with or without BEV, on GOG 218, a prospective phase III trial. Method: Pretreatment computed tomography (CT) for 1538 GOG 218 participants were analyzed. Proportional hazards models assessed association between adiposity and overall survival (OS) adjusted for other prognostic factors. The predictive value of adiposity as a function of BEV treatment was assessed in 1019 patients randomized to either chemotherapy (CT) + placebo (P) → P or CT + BEV → BEV. Results: After adjusting for prognostic factors, SFA was not associated with the overall hazard of death (p = 0.981). There was a non-significant 0.1% (p = 0.062) increase in hazard of death associated with a unit increase in VFA. When comparing the treatment HRs for patients who did and did not receive BEV, there was no association with SFA (p = 0.890) or VFA (p = 0.106). A non-significant 0.8% increase in the hazard of death with unit increase in BMI (p = 0.086) was observed. BMI values were not predictive of a longer survival for patients with BEV vs placebo (p = 0.606). Conclusion: Measures of adiposity strongly correlated to one another but were not predictive of efficacy for BEV. VFA is a weak prognostic factor.

AB - Objective: Adiposity has been hypothesized to interfere with the activity of bevacizumab (BEV), an anti-angiogenic agent. Measurements of adiposity, BMI, surface fat area (SFA), and visceral fat area (VFA) were investigated as prognostic of oncologic outcomes among patients treated with chemotherapy, with or without BEV, on GOG 218, a prospective phase III trial. Method: Pretreatment computed tomography (CT) for 1538 GOG 218 participants were analyzed. Proportional hazards models assessed association between adiposity and overall survival (OS) adjusted for other prognostic factors. The predictive value of adiposity as a function of BEV treatment was assessed in 1019 patients randomized to either chemotherapy (CT) + placebo (P) → P or CT + BEV → BEV. Results: After adjusting for prognostic factors, SFA was not associated with the overall hazard of death (p = 0.981). There was a non-significant 0.1% (p = 0.062) increase in hazard of death associated with a unit increase in VFA. When comparing the treatment HRs for patients who did and did not receive BEV, there was no association with SFA (p = 0.890) or VFA (p = 0.106). A non-significant 0.8% increase in the hazard of death with unit increase in BMI (p = 0.086) was observed. BMI values were not predictive of a longer survival for patients with BEV vs placebo (p = 0.606). Conclusion: Measures of adiposity strongly correlated to one another but were not predictive of efficacy for BEV. VFA is a weak prognostic factor.

KW - Adiposity

KW - Epithelial ovarian cancer

KW - NRG

KW - Prognostic biomarkers

UR - http://www.scopus.com/inward/record.url?scp=85070297174&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070297174&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2019.07.020

DO - 10.1016/j.ygyno.2019.07.020

M3 - Article

C2 - 31409486

AN - SCOPUS:85070297174

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

ER -